Breaking News1 year ago
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
[ad_1] Newswise — SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a...
